Brief Report: A Blood-Based MicroRNA Complementary Diagnostic Predicts Immunotherapy Efficacy in Advanced-Stage NSCLC With High Programmed Death-Ligand 1 Expression

INTRODUCTION: Patients with advanced, non-oncogene-driven NSCLC with high programmed death-ligand 1 (PD-L1) expression are eligible for treatment with immunotherapy. There is, however, an urgent medical need for biomarkers identifying cases that require additional combination with chemotherapy. We p...

Descripción completa

Detalles Bibliográficos
Autores principales: Rajakumar, Timothy, Horos, Rastislav, Kittner, Paul, Kahraman, Mustafa, Sikosek, Tobias, Hinkfoth, Franziska, Tikk, Kaja, Mercaldo, Nathaniel D., Stenzinger, Albrecht, Rabe, Klaus F., Reck, Martin, Thomas, Michael, Christopoulos, Petros, Steinkraus, Bruno R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9307680/
https://www.ncbi.nlm.nih.gov/pubmed/35880086
http://dx.doi.org/10.1016/j.jtocrr.2022.100369

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9307680/
https://www.ncbi.nlm.nih.gov/pubmed/35880086
http://dx.doi.org/10.1016/j.jtocrr.2022.100369

Ejemplares similares